Physician profile
Ryan Hightower
NPI 1225799935
$3,150.56
in general payments reported to CMS, 2019-2025
24 companies · $1,158 in 2025
The $1,158 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $82.65 · 2023: $954 · 2024: $956 · 2025: $1,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,067.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $461.92 | 2023-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $357.10 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $315.25 | 2023-2025 | |
| Amgen INC. | $236.30 | 2023-2025 | Evenity, Prolia, Prolia |
| Lilly USA, LLC | $209.73 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $203.51 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $194.82 | 2023-2025 | Trintellix |
| Glaxosmithkline, LLC. | $185.15 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.93 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Astellas Pharma US INC | $138.70 | 2023-2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $118.73 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $116.31 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $93.08 | 2024-2025 | Caplyta |
| Lundbeck LLC | $68.31 | 2023-2025 | Rexulti |
| Gilead Sciences, INC. | $49.37 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $45.36 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.21 | 2023-2024 | |
| Dexcom, INC. | $45.10 | 2024 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $29.30 | 2024-2025 | Zoryve, Livalo |
| Medtronic, INC. | $23.06 | 2025 | Intellis Adaptivestim |
| Sumitomo Pharma America, INC. | $21.12 | 2023 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $17.99 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $17.65 | 2025 | Voquezna |
| Boston Scientific Corporation | $16.56 | 2025 | Watchman Flx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Hightower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.